Multimodal Nanohybrid Artificial Antibodies as PD‐L1 Immune Checkpoint Antagonists for Potentiated Combination Cancer Immunotherapy

ABSTRACT Monoclonal antibody–based PD‐1/PD‐L1 blockade immunotherapy is an innovative approach to cancer treatment. However, its clinical efficacy remains limited, with low response rates in patients, requiring multimodal therapeutic approaches. This study reports the development of synthetic nanohybrid artificial antibodies (SNA) with both PD‐L1 blockade and photothermal effects as multimodal immune checkpoint antagonists for effective combination cancer immunotherapy. Multimodal SNAs are prepared by assembling multivalent tripeptide recognition phases onto rigid scaffolds of WS 2 or MoSe 2 nanosheets with photothermal effect. The SNAs, comprising an FNP tripeptide assembly on nanosheets (MoSe 2 ‐FNP & WS 2 ‐FNP), selectively bind to PD‐L1 with sub‐nanomolar apparent affinity (0.785 nM), thereby effectively blocking its interaction with PD‐1 on T cells. Thorough experimental and computational results reveal that the recognition selectivity of the SNAs for PD‐L1 is attributed to their multivalent hydrogen bonds and hydrophobic interactions with the PD‐L1 epitope. The multimodal MoSe 2 ‐FNP more effectively eradicates tumor cells by combining a PD‐L1 blockade with photothermal effect. The multimodal MoSe 2 ‐FNP‐based combination immunotherapy accelerates the infiltration of antitumoral immune cells into solid tumors in mice, and its therapeutic efficacy is significantly enhanced compared with monoclonal antibody treatment. This SNA‐based cancer immunotherapy thus holds considerable promise as an effective therapeutic avenue for cancer treatment.

Authors

Institutions

Publication Details

Journal
Small
Published
2026-11-16
DOI
https://doi.org/10.1002/smll.76751
Primary Topic
Nanoplatforms for cancer theranostics
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Multimodal Nanohybrid Artificial Antibodies as PD‐L1 Immune Checkpoint Antagonists for Potentiated Combination Cancer Immunotherapy

Hongwon Kim, Hwankyu Lee, Yoonhee So, Sin Lee et al.
1 links
Small
Nanoplatforms for cancer theranostics
article

Multimodal Nanohybrid Artificial Antibodies as PD‐L1 Immune Checkpoint Antagonists for Potentiated Combination Cancer Immunotherapy

Hongwon Kim, Hwankyu Lee, Yoonhee So, Sin Lee, Yejoo Yu, Jong‐Ho Kim, Chanhee Choi, Sohyun Moon, Yujin Choi, Seongyeon Choi
article en

Abstract

ABSTRACT Monoclonal antibody–based PD‐1/PD‐L1 blockade immunotherapy is an innovative approach to cancer treatment. However, its clinical efficacy remains limited, with low response rates in patients, requiring multimodal therapeutic approaches. This study reports the development of synthetic nanohybrid artificial antibodies (SNA) with both PD‐L1 blockade and photothermal effects as multimodal immune checkpoint antagonists for effective combination cancer immunotherapy. Multimodal SNAs are prepared by assembling multivalent tripeptide recognition phases onto rigid scaffolds of WS 2 or MoSe 2 nanosheets with photothermal effect. The SNAs, comprising an FNP tripeptide assembly on nanosheets (MoSe 2 ‐FNP & WS 2 ‐FNP), selectively bind to PD‐L1 with sub‐nanomolar apparent affinity (0.785 nM), thereby effectively blocking its interaction with PD‐1 on T cells. Thorough experimental and computational results reveal that the recognition selectivity of the SNAs for PD‐L1 is attributed to their multivalent hydrogen bonds and hydrophobic interactions with the PD‐L1 epitope. The multimodal MoSe 2 ‐FNP more effectively eradicates tumor cells by combining a PD‐L1 blockade with photothermal effect. The multimodal MoSe 2 ‐FNP‐based combination immunotherapy accelerates the infiltration of antitumoral immune cells into solid tumors in mice, and its therapeutic efficacy is significantly enhanced compared with monoclonal antibody treatment. This SNA‐based cancer immunotherapy thus holds considerable promise as an effective therapeutic avenue for cancer treatment.

Small
Hanyang University (KR), Massachusetts Institute of Technology (US), Dankook University (KR)
Good health and well-being
Nanoplatforms for cancer theranostics
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon